1783 Stock Overview
Researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 1783 from our risk checks.
Maxigen Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$41.90 |
| 52 Week High | NT$51.50 |
| 52 Week Low | NT$37.25 |
| Beta | 0.89 |
| 11 Month Change | -1.53% |
| 3 Month Change | -3.01% |
| 1 Year Change | -11.51% |
| 33 Year Change | -14.19% |
| 5 Year Change | 95.93% |
| Change since IPO | -3.79% |
Recent News & Updates
Recent updates
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality
Mar 28
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?
Apr 22We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings
Apr 01Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Mar 16The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More
Feb 23Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?
Feb 02Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield
Jan 10Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?
Dec 14If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%
Nov 22
Shareholder Returns
| 1783 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -4.3% | -3.8% | -3.4% |
| 1Y | -11.5% | 2.1% | 30.2% |
Return vs Industry: 1783 underperformed the TW Biotechs industry which returned 2.1% over the past year.
Return vs Market: 1783 underperformed the TW Market which returned 30.2% over the past year.
Price Volatility
| 1783 volatility | |
|---|---|
| 1783 Average Weekly Movement | 2.9% |
| Biotechs Industry Average Movement | 4.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1783 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1783's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Ching-Ting Chen | mbi-bio.com |
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; and BestAid, a collagen bone graft.
Maxigen Biotech Inc. Fundamentals Summary
| 1783 fundamental statistics | |
|---|---|
| Market cap | NT$3.73b |
| Earnings (TTM) | NT$147.18m |
| Revenue (TTM) | NT$609.24m |
25.4x
P/E Ratio6.1x
P/S RatioIs 1783 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1783 income statement (TTM) | |
|---|---|
| Revenue | NT$609.24m |
| Cost of Revenue | NT$194.12m |
| Gross Profit | NT$415.13m |
| Other Expenses | NT$267.95m |
| Earnings | NT$147.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.65 |
| Gross Margin | 68.14% |
| Net Profit Margin | 24.16% |
| Debt/Equity Ratio | 0% |
How did 1783 perform over the long term?
See historical performance and comparison